CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
Go back to CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study| CEL-SCI CORPORATION (NYSE: CVM) | Delayed: 1.49 +0.01 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.48 | 52 Week High | $0.66 | |||
| Open | $1.51 | 52 Week Low | $0.20 | |||
| Day High | $1.57 | P/E | N/A | |||
| Day Low | $1.49 | EPS | $-0.34 | |||
| Volume | 43,173 | |||||
